Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment - Seite 3

Intermountain Healthcare media contact: Brad Gillman: [e-mail] / [phone]

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that patients with locally advanced or metastatic cancer with eligible genetic testing completed through Intermountain or Myriad may have the opportunity to enroll in the ComboMATCH Patient Registration Trial. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on March 1, 2023, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Media Contact:
Glenn Farrell
[phone]
[e-mail]

Investor Contact:
Matt Scalo
[phone]
[e-mail]